Evidence map›Paper›PMID 24100126›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2014

Development of reduced kidney function in rheumatoid arthritis.

LaTonya J Hickson, Cynthia S Crowson, Sherine E Gabriel, James T McCarthy, Eric L Matteson

Open access · greenAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Associations ofGenes · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

LaTonya J HicksonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address: hickson.latonya@mayo.edu.
Cynthia S CrowsonDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Division of Rheumatology, Mayo Clinic, Rochester, MN.
Sherine E GabrielDivision of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN.
James T McCarthyDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Eric L MattesonDivision of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN; Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN.
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

HEART DISEASE IN RHEUMATOID ARTHRITISR01AR046849 · NIAMS · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2000 to 2022
$11.3M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
NIAMS NIH HHS R01 AR046849NIAMS NIH HHS R01AR46849NIA NIH HHS R01 AG034676NIA NIH HHS R01AG034676
6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is associated with a variety of kidney disorders. However, it is unclear whether the development of reduced kidney function is higher in patients with RA compared to the general population. STUDY

designRetrospective review. SETTING &

participantsIncident adult-onset RA cases (813) and a comparison cohort of non-RA individuals (813) in Olmsted County, MN, in 1980-2007. PREDICTOR: Baseline demographic and clinical variables. OUTCOMES: Reduced kidney function: (1) estimated glomerular filtration rate (eGFR)<60mL/min/1.73m(2) and (2) eGFR<45mL/min/1.73m(2) on 2 consecutive occasions at least 90 days apart; cardiovascular disease (CVD); and death. MEASUREMENTS: The cumulative incidence of reduced kidney function was estimated adjusting for the competing risk of death.

resultsOf 813 patients with RA and 813 non-RA individuals, mean age was 56±16 (SD) years, 68% were women, and 9% had reduced kidney function at baseline. The 20-year cumulative incidence of reduced kidney function was higher in patients with RA compared with non-RA participants for eGFR < 60mL/min/1.73m(2) (25% vs 20%; P=0.03), but not eGFR<45mL/min/1.73m(2) (9% vs 10%; P=0.8). The presence of CVD at baseline (HR, 1.77; 95% CI, 1.14-2.73; P=0.01) and elevated erythrocyte sedimentation rate in patients with RA (HR per 10-mm/h increase, 1.08; 95% CI, 1.00-1.16; P=0.04) was associated with increased risk of eGFR<60mL/min/1.73m(2). eGFR<60mL/min/1.73m(2) was not associated with increased risk of CVD development in patients with RA (HR, 0.99; 95% CI, 0.63-1.57; P=0.9), however, a greater reduction in GFR (eGFR<45mL/min/1.73m(2)) was associated with increased risk of CVD (HR, 1.93; CI, 1.04-3.58; P=0.04). LIMITATIONS: Reduced kidney function was defined by estimating equations for kidney function. We are limited to deriving associations from our findings.

conclusionsPatients with RA were more likely to develop reduced kidney function over time. CVD and associated factors appear to play a role. The presence of RA in individuals with reduced kidney function may lead to an increase in morbidity from CVD development, for which awareness may provide a means for optimizing care.

Indexed as

AdultAgedArthritis, RheumatoidCohort StudiesFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedRetrospective StudiesCardiovascular diseaseestimated glomerular filtration rate (eGFR)glomerulonephritiskidney dysfunctionmortalityrenal progressionrheumatoid arthritis (RA)

Identifiers

PMID24100126
PMCPMC3944015
OpenAlexW2116777373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.